Research Article
Published: 02 June, 2025 | Volume 9 - Issue 1 | Pages: 004-012
Background: Monotherapy for liver dysfunction in diabetes is less effective. This study investigated the effect of combined linagliptin and metformin therapy on liver function in diabetic rats.
Methods and materials: Sixty-four matured male (200-300 g) Wistar rats were used. Diabetes was induced with 35 mg/kb.wt streptozotocin injected intraperitoneally. The rats were grouped into eight groups (n = 8). Group I: control; Group II: control + 10 mg/kg body weight linagliptin; Group III: control + 200 mg/kg body weight metformin; Group IV; control + 10 mg/kg body weight linagliptin + 200 mg/kg body weight metformin; Group V: diabetic; Group VI: diabetic + 10 mg/kg body weight linagliptin; Group VII: diabetic + 200 mg/kg body weight metformin; Group VIII: diabetic + 10 mg/kg body weight linagliptin + 200 mg/kg body weight metformin. After the animal was sacrificed, blood and liver samples were collected for biochemical assay.
Results: Insulin, blood glucose, glycated hemoglobin, total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-cholesterol), liver enzymes (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, lactate dehydrogenase, pyruvate kinase, glucose-6-phosphatase dehydrogenase, malondialdehyde and inflammatory makers increased (p < 0.05) significantly. High-density lipoprotein-cholesterol (HDL-cholesterol), liver antioxidant, glycogen, and glycogen synthase were reduced significantly in diabetic rats. Linagliptin and metformin administration single and combined reduced the insulin, blood glucose, glycated hemoglobin, total cholesterol, triglycerides, LDL-cholesterol, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, lactate dehydrogenase, pyruvate kinase, glucose-6-phosphatase dehydrogenase, malondialdehyde, inflammatory makers and increased the HDL-cholesterol, liver antioxidant, glycogen and glycogen synthase in diabetic rats.
Conclusion: Linagliptin monotherapy alone efficiently controls hyperglycemia and remarkably improves liver functions. Combining linagliptin and metformin could be used as safe and effective therapy for liver dysfunction progression in diabetes.
Read Full Article HTML DOI: 10.29328/journal.acgh.1001050 Cite this Article Read Full Article PDF
Diabetes; Liver function; Dyslipidemia; Oxidative stress and inflammation; Linagliptin-metformin
Figure 1
Figure 2
HSPI: We're glad you're here. Please click "create a new Query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."